|
| | SB3109 Enrolled | | LRB098 18318 ZMM 53453 b |
|
|
1 | | AN ACT concerning regulation.
|
2 | | Be it enacted by the People of the State of Illinois,
|
3 | | represented in the General Assembly:
|
4 | | Section 5. The Illinois Optometric Practice Act of 1987 is |
5 | | amended by changing Section 15.1 as follows:
|
6 | | (225 ILCS 80/15.1)
|
7 | | (Section scheduled to be repealed on January 1, 2017)
|
8 | | Sec. 15.1. Diagnostic and therapeutic authority.
|
9 | | (a) For purposes of the Act, "ocular pharmaceutical
agents" |
10 | | means topical anesthetics, topical mydriatics, topical
|
11 | | cycloplegics, topical miotics and mydriatic reversing agents, |
12 | | anti-infective agents,
anti-allergy agents,
anti-glaucoma |
13 | | agents (except oral carbonic anhydrase inhibitors, which may be |
14 | | prescribed only in a quantity sufficient to provide treatment |
15 | | for up to 72 hours),
anti-inflammatory agents (except oral |
16 | | steroids), over-the-counter agents, analgesic
agents, anti-dry |
17 | | eye agents, and agents for the treatment of hypotrichosis. |
18 | | (a-3) In addition to ocular pharmaceutical agents that fall |
19 | | within the categories set forth in subsection (a) of this |
20 | | Section, the Board may add a pharmaceutical agent approved by |
21 | | the FDA or class of agents for the purpose of the diagnosis or |
22 | | treatment of conditions of the eye and adnexa after |
23 | | consideration of the agent's systemic effects, side effects, |
|
| | SB3109 Enrolled | - 2 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | and the use of the agent within the practice of optometry. The |
2 | | Board shall consider requests for additional agents and make |
3 | | recommendations within 90 days after the receipt of the |
4 | | request. |
5 | | Within 45 days after the Board's recommendation to the |
6 | | Department of a pharmaceutical agent or class of agents, the |
7 | | Department shall promulgate rules necessary to allow for the |
8 | | prescribing or administering of the pharmaceutical agent or |
9 | | class of agents under this Act. |
10 | | (a-5) Ocular pharmaceutical agents administered by |
11 | | injection may be used only for the treatment of anaphylaxis. |
12 | | (a-10) Oral pharmaceutical agents may be prescribed for a |
13 | | child under 5 years of age only in consultation with a |
14 | | physician licensed to practice medicine in all its branches. |
15 | | (a-15) The authority to prescribe a Schedule III, IV, or V |
16 | | controlled substance shall include only analgesic agents only |
17 | | in a quantity sufficient to provide treatment for up to 72 |
18 | | hours. The prescription of a Schedule II controlled substance |
19 | | is prohibited , except for Dihydrocodeinone (Hydrocodone) with |
20 | | one or more active, non-narcotic ingredients only in a quantity |
21 | | sufficient to provide treatment for up to 72 hours, and only if |
22 | | such formulations of Dihydrocodeinone are reclassified as |
23 | | Schedule II by federal regulation .
|
24 | | (b) A licensed optometrist may remove superficial foreign |
25 | | bodies from the human eye and adnexa and may give orders for |
26 | | patient care to a nurse licensed to practice under Illinois |
|
| | SB3109 Enrolled | - 3 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | law.
|
2 | | (c) An optometrist's license shall be revoked or suspended |
3 | | by the Department
upon recommendation of the Board based upon |
4 | | either of the
following causes: |
5 | | (1) grave or repeated misuse of any ocular
|
6 | | pharmaceutical agent; and |
7 | | (2) the use of any agent or procedure in the course of |
8 | | optometric practice
by an optometrist not properly |
9 | | authorized under this Act. |
10 | | (d) The Secretary of Financial and Professional Regulation |
11 | | shall notify
the Director of Public Health as to the categories |
12 | | of ocular
pharmaceutical agents permitted for use by an |
13 | | optometrist. The Director of Public Health shall in turn
notify |
14 | | every licensed pharmacist in the State of the categories of |
15 | | ocular
pharmaceutical agents that can be utilized and |
16 | | prescribed by an optometrist.
|
17 | | (Source: P.A. 97-170, eff. 7-22-11.)
|
18 | | Section 10. The Illinois Controlled Substances Act is |
19 | | amended by changing Section 102 as follows: |
20 | | (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102) |
21 | | Sec. 102. Definitions. As used in this Act, unless the |
22 | | context
otherwise requires:
|
23 | | (a) "Addict" means any person who habitually uses any drug, |
24 | | chemical,
substance or dangerous drug other than alcohol so as |
|
| | SB3109 Enrolled | - 4 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | to endanger the public
morals, health, safety or welfare or who |
2 | | is so far addicted to the use of a
dangerous drug or controlled |
3 | | substance other than alcohol as to have lost
the power of self |
4 | | control with reference to his or her addiction.
|
5 | | (b) "Administer" means the direct application of a |
6 | | controlled
substance, whether by injection, inhalation, |
7 | | ingestion, or any other
means, to the body of a patient, |
8 | | research subject, or animal (as
defined by the Humane |
9 | | Euthanasia in Animal Shelters Act) by:
|
10 | | (1) a practitioner (or, in his or her presence, by his |
11 | | or her authorized agent),
|
12 | | (2) the patient or research subject pursuant to an |
13 | | order, or
|
14 | | (3) a euthanasia technician as defined by the Humane |
15 | | Euthanasia in
Animal Shelters Act.
|
16 | | (c) "Agent" means an authorized person who acts on behalf |
17 | | of or at
the direction of a manufacturer, distributor, |
18 | | dispenser, prescriber, or practitioner. It does not
include a |
19 | | common or contract carrier, public warehouseman or employee of
|
20 | | the carrier or warehouseman.
|
21 | | (c-1) "Anabolic Steroids" means any drug or hormonal |
22 | | substance,
chemically and pharmacologically related to |
23 | | testosterone (other than
estrogens, progestins, |
24 | | corticosteroids, and dehydroepiandrosterone),
and includes:
|
25 | | (i) 3[beta],17-dihydroxy-5a-androstane, |
26 | | (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, |
|
| | SB3109 Enrolled | - 5 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | (iii) 5[alpha]-androstan-3,17-dione, |
2 | | (iv) 1-androstenediol (3[beta], |
3 | | 17[beta]-dihydroxy-5[alpha]-androst-1-ene), |
4 | | (v) 1-androstenediol (3[alpha], |
5 | | 17[beta]-dihydroxy-5[alpha]-androst-1-ene), |
6 | | (vi) 4-androstenediol |
7 | | (3[beta],17[beta]-dihydroxy-androst-4-ene), |
8 | | (vii) 5-androstenediol |
9 | | (3[beta],17[beta]-dihydroxy-androst-5-ene), |
10 | | (viii) 1-androstenedione |
11 | | ([5alpha]-androst-1-en-3,17-dione), |
12 | | (ix) 4-androstenedione |
13 | | (androst-4-en-3,17-dione), |
14 | | (x) 5-androstenedione |
15 | | (androst-5-en-3,17-dione), |
16 | | (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- |
17 | | hydroxyandrost-4-en-3-one), |
18 | | (xii) boldenone (17[beta]-hydroxyandrost- |
19 | | 1,4,-diene-3-one), |
20 | | (xiii) boldione (androsta-1,4- |
21 | | diene-3,17-dione), |
22 | | (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 |
23 | | [beta]-hydroxyandrost-4-en-3-one), |
24 | | (xv) clostebol (4-chloro-17[beta]- |
25 | | hydroxyandrost-4-en-3-one), |
26 | | (xvi) dehydrochloromethyltestosterone (4-chloro- |
|
| | SB3109 Enrolled | - 6 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | 17[beta]-hydroxy-17[alpha]-methyl- |
2 | | androst-1,4-dien-3-one), |
3 | | (xvii) desoxymethyltestosterone |
4 | | (17[alpha]-methyl-5[alpha] |
5 | | -androst-2-en-17[beta]-ol)(a.k.a., madol), |
6 | | (xviii) [delta]1-dihydrotestosterone (a.k.a. |
7 | | '1-testosterone') (17[beta]-hydroxy- |
8 | | 5[alpha]-androst-1-en-3-one), |
9 | | (xix) 4-dihydrotestosterone (17[beta]-hydroxy- |
10 | | androstan-3-one), |
11 | | (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- |
12 | | 5[alpha]-androstan-3-one), |
13 | | (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- |
14 | | hydroxyestr-4-ene), |
15 | | (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- |
16 | | 1[beta],17[beta]-dihydroxyandrost-4-en-3-one), |
17 | | (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], |
18 | | 17[beta]-dihydroxyandrost-1,4-dien-3-one), |
19 | | (xxiv) furazabol (17[alpha]-methyl-17[beta]- |
20 | | hydroxyandrostano[2,3-c]-furazan), |
21 | | (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one) |
22 | | (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- |
23 | | androst-4-en-3-one), |
24 | | (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- |
25 | | dihydroxy-estr-4-en-3-one), |
26 | | (xxviii) mestanolone (17[alpha]-methyl-17[beta]- |
|
| | SB3109 Enrolled | - 7 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | hydroxy-5-androstan-3-one), |
2 | | (xxix) mesterolone (1amethyl-17[beta]-hydroxy- |
3 | | [5a]-androstan-3-one), |
4 | | (xxx) methandienone (17[alpha]-methyl-17[beta]- |
5 | | hydroxyandrost-1,4-dien-3-one), |
6 | | (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- |
7 | | dihydroxyandrost-5-ene), |
8 | | (xxxii) methenolone (1-methyl-17[beta]-hydroxy- |
9 | | 5[alpha]-androst-1-en-3-one), |
10 | | (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- |
11 | | dihydroxy-5a-androstane), |
12 | | (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy |
13 | | -5a-androstane), |
14 | | (xxxv) 17[alpha]-methyl-3[beta],17[beta]- |
15 | | dihydroxyandrost-4-ene), |
16 | | (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- |
17 | | methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), |
18 | | (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- |
19 | | hydroxyestra-4,9(10)-dien-3-one), |
20 | | (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- |
21 | | hydroxyestra-4,9-11-trien-3-one), |
22 | | (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- |
23 | | hydroxyandrost-4-en-3-one), |
24 | | (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- |
25 | | hydroxyestr-4-en-3-one), |
26 | | (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone |
|
| | SB3109 Enrolled | - 8 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- |
2 | | androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- |
3 | | 1-testosterone'), |
4 | | (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), |
5 | | (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- |
6 | | dihydroxyestr-4-ene), |
7 | | (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- |
8 | | dihydroxyestr-4-ene), |
9 | | (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- |
10 | | dihydroxyestr-5-ene), |
11 | | (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- |
12 | | dihydroxyestr-5-ene), |
13 | | (xlvii) 19-nor-4,9(10)-androstadienedione |
14 | | (estra-4,9(10)-diene-3,17-dione), |
15 | | (xlviii) 19-nor-4-androstenedione (estr-4- |
16 | | en-3,17-dione), |
17 | | (xlix) 19-nor-5-androstenedione (estr-5- |
18 | | en-3,17-dione), |
19 | | (l) norbolethone (13[beta], 17a-diethyl-17[beta]- |
20 | | hydroxygon-4-en-3-one), |
21 | | (li) norclostebol (4-chloro-17[beta]- |
22 | | hydroxyestr-4-en-3-one), |
23 | | (lii) norethandrolone (17[alpha]-ethyl-17[beta]- |
24 | | hydroxyestr-4-en-3-one), |
25 | | (liii) normethandrolone (17[alpha]-methyl-17[beta]- |
26 | | hydroxyestr-4-en-3-one), |
|
| | SB3109 Enrolled | - 9 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- |
2 | | 2-oxa-5[alpha]-androstan-3-one), |
3 | | (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- |
4 | | dihydroxyandrost-4-en-3-one), |
5 | | (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- |
6 | | 17[beta]-hydroxy-(5[alpha]-androstan-3-one), |
7 | | (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- |
8 | | (5[alpha]-androst-2-eno[3,2-c]-pyrazole), |
9 | | (lviii) stenbolone (17[beta]-hydroxy-2-methyl- |
10 | | (5[alpha]-androst-1-en-3-one), |
11 | | (lix) testolactone (13-hydroxy-3-oxo-13,17- |
12 | | secoandrosta-1,4-dien-17-oic |
13 | | acid lactone), |
14 | | (lx) testosterone (17[beta]-hydroxyandrost- |
15 | | 4-en-3-one), |
16 | | (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- |
17 | | diethyl-17[beta]-hydroxygon- |
18 | | 4,9,11-trien-3-one), |
19 | | (lxii) trenbolone (17[beta]-hydroxyestr-4,9, |
20 | | 11-trien-3-one).
|
21 | | Any person who is otherwise lawfully in possession of an |
22 | | anabolic
steroid, or who otherwise lawfully manufactures, |
23 | | distributes, dispenses,
delivers, or possesses with intent to |
24 | | deliver an anabolic steroid, which
anabolic steroid is |
25 | | expressly intended for and lawfully allowed to be
administered |
26 | | through implants to livestock or other nonhuman species, and
|
|
| | SB3109 Enrolled | - 10 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | which is approved by the Secretary of Health and Human Services |
2 | | for such
administration, and which the person intends to |
3 | | administer or have
administered through such implants, shall |
4 | | not be considered to be in
unauthorized possession or to |
5 | | unlawfully manufacture, distribute, dispense,
deliver, or |
6 | | possess with intent to deliver such anabolic steroid for
|
7 | | purposes of this Act.
|
8 | | (d) "Administration" means the Drug Enforcement |
9 | | Administration,
United States Department of Justice, or its |
10 | | successor agency.
|
11 | | (d-5) "Clinical Director, Prescription Monitoring Program" |
12 | | means a Department of Human Services administrative employee |
13 | | licensed to either prescribe or dispense controlled substances |
14 | | who shall run the clinical aspects of the Department of Human |
15 | | Services Prescription Monitoring Program and its Prescription |
16 | | Information Library. |
17 | | (d-10) "Compounding" means the preparation and mixing of |
18 | | components, excluding flavorings, (1) as the result of a |
19 | | prescriber's prescription drug order or initiative based on the |
20 | | prescriber-patient-pharmacist relationship in the course of |
21 | | professional practice or (2) for the purpose of, or incident |
22 | | to, research, teaching, or chemical analysis and not for sale |
23 | | or dispensing. "Compounding" includes the preparation of drugs |
24 | | or devices in anticipation of receiving prescription drug |
25 | | orders based on routine, regularly observed dispensing |
26 | | patterns. Commercially available products may be compounded |
|
| | SB3109 Enrolled | - 11 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | for dispensing to individual patients only if both of the |
2 | | following conditions are met: (i) the commercial product is not |
3 | | reasonably available from normal distribution channels in a |
4 | | timely manner to meet the patient's needs and (ii) the |
5 | | prescribing practitioner has requested that the drug be |
6 | | compounded. |
7 | | (e) "Control" means to add a drug or other substance, or |
8 | | immediate
precursor, to a Schedule whether by
transfer from |
9 | | another Schedule or otherwise.
|
10 | | (f) "Controlled Substance" means (i) a drug, substance, or |
11 | | immediate
precursor in the Schedules of Article II of this Act |
12 | | or (ii) a drug or other substance, or immediate precursor, |
13 | | designated as a controlled substance by the Department through |
14 | | administrative rule. The term does not include distilled |
15 | | spirits, wine, malt beverages, or tobacco, as those terms are
|
16 | | defined or used in the Liquor Control Act of 1934 and the |
17 | | Tobacco Products Tax
Act of 1995 .
|
18 | | (f-5) "Controlled substance analog" means a substance: |
19 | | (1) the chemical structure of which is substantially |
20 | | similar to the chemical structure of a controlled substance |
21 | | in Schedule I or II; |
22 | | (2) which has a stimulant, depressant, or |
23 | | hallucinogenic effect on the central nervous system that is |
24 | | substantially similar to or greater than the stimulant, |
25 | | depressant, or hallucinogenic effect on the central |
26 | | nervous system of a controlled substance in Schedule I or |
|
| | SB3109 Enrolled | - 12 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | II; or |
2 | | (3) with respect to a particular person, which such |
3 | | person represents or intends to have a stimulant, |
4 | | depressant, or hallucinogenic effect on the central |
5 | | nervous system that is substantially similar to or greater |
6 | | than the stimulant, depressant, or hallucinogenic effect |
7 | | on the central nervous system of a controlled substance in |
8 | | Schedule I or II. |
9 | | (g) "Counterfeit substance" means a controlled substance, |
10 | | which, or
the container or labeling of which, without |
11 | | authorization bears the
trademark, trade name, or other |
12 | | identifying mark, imprint, number or
device, or any likeness |
13 | | thereof, of a manufacturer, distributor, or
dispenser other |
14 | | than the person who in fact manufactured, distributed,
or |
15 | | dispensed the substance.
|
16 | | (h) "Deliver" or "delivery" means the actual, constructive |
17 | | or
attempted transfer of possession of a controlled substance, |
18 | | with or
without consideration, whether or not there is an |
19 | | agency relationship.
|
20 | | (i) "Department" means the Illinois Department of Human |
21 | | Services (as
successor to the Department of Alcoholism and |
22 | | Substance Abuse) or its successor agency.
|
23 | | (j) (Blank).
|
24 | | (k) "Department of Corrections" means the Department of |
25 | | Corrections
of the State of Illinois or its successor agency.
|
26 | | (l) "Department of Financial and Professional Regulation" |
|
| | SB3109 Enrolled | - 13 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | means the Department
of Financial and Professional Regulation |
2 | | of the State of Illinois or its successor agency.
|
3 | | (m) "Depressant" means any drug that (i) causes an overall |
4 | | depression of central nervous system functions, (ii) causes |
5 | | impaired consciousness and awareness, and (iii) can be |
6 | | habit-forming or lead to a substance abuse problem, including |
7 | | but not limited to alcohol, cannabis and its active principles |
8 | | and their analogs, benzodiazepines and their analogs, |
9 | | barbiturates and their analogs, opioids (natural and |
10 | | synthetic) and their analogs, and chloral hydrate and similar |
11 | | sedative hypnotics.
|
12 | | (n) (Blank).
|
13 | | (o) "Director" means the Director of the Illinois State |
14 | | Police or his or her designated agents.
|
15 | | (p) "Dispense" means to deliver a controlled substance to |
16 | | an
ultimate user or research subject by or pursuant to the |
17 | | lawful order of
a prescriber, including the prescribing, |
18 | | administering, packaging,
labeling, or compounding necessary |
19 | | to prepare the substance for that
delivery.
|
20 | | (q) "Dispenser" means a practitioner who dispenses.
|
21 | | (r) "Distribute" means to deliver, other than by |
22 | | administering or
dispensing, a controlled substance.
|
23 | | (s) "Distributor" means a person who distributes.
|
24 | | (t) "Drug" means (1) substances recognized as drugs in the |
25 | | official
United States Pharmacopoeia, Official Homeopathic |
26 | | Pharmacopoeia of the
United States, or official National |
|
| | SB3109 Enrolled | - 14 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | Formulary, or any supplement to any
of them; (2) substances |
2 | | intended for use in diagnosis, cure, mitigation,
treatment, or |
3 | | prevention of disease in man or animals; (3) substances
(other |
4 | | than food) intended to affect the structure of any function of
|
5 | | the body of man or animals and (4) substances intended for use |
6 | | as a
component of any article specified in clause (1), (2), or |
7 | | (3) of this
subsection. It does not include devices or their |
8 | | components, parts, or
accessories.
|
9 | | (t-5) "Euthanasia agency" means
an entity certified by the |
10 | | Department of Financial and Professional Regulation for the
|
11 | | purpose of animal euthanasia that holds an animal control |
12 | | facility license or
animal
shelter license under the Animal |
13 | | Welfare Act. A euthanasia agency is
authorized to purchase, |
14 | | store, possess, and utilize Schedule II nonnarcotic and
|
15 | | Schedule III nonnarcotic drugs for the sole purpose of animal |
16 | | euthanasia.
|
17 | | (t-10) "Euthanasia drugs" means Schedule II or Schedule III |
18 | | substances
(nonnarcotic controlled substances) that are used |
19 | | by a euthanasia agency for
the purpose of animal euthanasia.
|
20 | | (u) "Good faith" means the prescribing or dispensing of a |
21 | | controlled
substance by a practitioner in the regular course of |
22 | | professional
treatment to or for any person who is under his or |
23 | | her treatment for a
pathology or condition other than that |
24 | | individual's physical or
psychological dependence upon or |
25 | | addiction to a controlled substance,
except as provided herein: |
26 | | and application of the term to a pharmacist
shall mean the |
|
| | SB3109 Enrolled | - 15 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | dispensing of a controlled substance pursuant to the
|
2 | | prescriber's order which in the professional judgment of the |
3 | | pharmacist
is lawful. The pharmacist shall be guided by |
4 | | accepted professional
standards including, but not limited to |
5 | | the following, in making the
judgment:
|
6 | | (1) lack of consistency of prescriber-patient |
7 | | relationship,
|
8 | | (2) frequency of prescriptions for same drug by one |
9 | | prescriber for
large numbers of patients,
|
10 | | (3) quantities beyond those normally prescribed,
|
11 | | (4) unusual dosages (recognizing that there may be |
12 | | clinical circumstances where more or less than the usual |
13 | | dose may be used legitimately),
|
14 | | (5) unusual geographic distances between patient, |
15 | | pharmacist and
prescriber,
|
16 | | (6) consistent prescribing of habit-forming drugs.
|
17 | | (u-0.5) "Hallucinogen" means a drug that causes markedly |
18 | | altered sensory perception leading to hallucinations of any |
19 | | type. |
20 | | (u-1) "Home infusion services" means services provided by a |
21 | | pharmacy in
compounding solutions for direct administration to |
22 | | a patient in a private
residence, long-term care facility, or |
23 | | hospice setting by means of parenteral,
intravenous, |
24 | | intramuscular, subcutaneous, or intraspinal infusion.
|
25 | | (u-5) "Illinois State Police" means the State
Police of the |
26 | | State of Illinois, or its successor agency. |
|
| | SB3109 Enrolled | - 16 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | (v) "Immediate precursor" means a substance:
|
2 | | (1) which the Department has found to be and by rule |
3 | | designated as
being a principal compound used, or produced |
4 | | primarily for use, in the
manufacture of a controlled |
5 | | substance;
|
6 | | (2) which is an immediate chemical intermediary used or |
7 | | likely to
be used in the manufacture of such controlled |
8 | | substance; and
|
9 | | (3) the control of which is necessary to prevent, |
10 | | curtail or limit
the manufacture of such controlled |
11 | | substance.
|
12 | | (w) "Instructional activities" means the acts of teaching, |
13 | | educating
or instructing by practitioners using controlled |
14 | | substances within
educational facilities approved by the State |
15 | | Board of Education or
its successor agency.
|
16 | | (x) "Local authorities" means a duly organized State, |
17 | | County or
Municipal peace unit or police force.
|
18 | | (y) "Look-alike substance" means a substance, other than a |
19 | | controlled
substance which (1) by overall dosage unit |
20 | | appearance, including shape,
color, size, markings or lack |
21 | | thereof, taste, consistency, or any other
identifying physical |
22 | | characteristic of the substance, would lead a reasonable
person |
23 | | to believe that the substance is a controlled substance, or (2) |
24 | | is
expressly or impliedly represented to be a controlled |
25 | | substance or is
distributed under circumstances which would |
26 | | lead a reasonable person to
believe that the substance is a |
|
| | SB3109 Enrolled | - 17 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | controlled substance. For the purpose of
determining whether |
2 | | the representations made or the circumstances of the
|
3 | | distribution would lead a reasonable person to believe the |
4 | | substance to be
a controlled substance under this clause (2) of |
5 | | subsection (y), the court or
other authority may consider the |
6 | | following factors in addition to any other
factor that may be |
7 | | relevant:
|
8 | | (a) statements made by the owner or person in control |
9 | | of the substance
concerning its nature, use or effect;
|
10 | | (b) statements made to the buyer or recipient that the |
11 | | substance may
be resold for profit;
|
12 | | (c) whether the substance is packaged in a manner |
13 | | normally used for the
illegal distribution of controlled |
14 | | substances;
|
15 | | (d) whether the distribution or attempted distribution |
16 | | included an
exchange of or demand for money or other |
17 | | property as consideration, and
whether the amount of the |
18 | | consideration was substantially greater than the
|
19 | | reasonable retail market value of the substance.
|
20 | | Clause (1) of this subsection (y) shall not apply to a |
21 | | noncontrolled
substance in its finished dosage form that was |
22 | | initially introduced into
commerce prior to the initial |
23 | | introduction into commerce of a controlled
substance in its |
24 | | finished dosage form which it may substantially resemble.
|
25 | | Nothing in this subsection (y) prohibits the dispensing or |
26 | | distributing
of noncontrolled substances by persons authorized |
|
| | SB3109 Enrolled | - 18 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | to dispense and
distribute controlled substances under this |
2 | | Act, provided that such action
would be deemed to be carried |
3 | | out in good faith under subsection (u) if the
substances |
4 | | involved were controlled substances.
|
5 | | Nothing in this subsection (y) or in this Act prohibits the |
6 | | manufacture,
preparation, propagation, compounding, |
7 | | processing, packaging, advertising
or distribution of a drug or |
8 | | drugs by any person registered pursuant to
Section 510 of the |
9 | | Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
|
10 | | (y-1) "Mail-order pharmacy" means a pharmacy that is |
11 | | located in a state
of the United States that delivers, |
12 | | dispenses or
distributes, through the United States Postal |
13 | | Service or other common
carrier, to Illinois residents, any |
14 | | substance which requires a prescription.
|
15 | | (z) "Manufacture" means the production, preparation, |
16 | | propagation,
compounding, conversion or processing of a |
17 | | controlled substance other than methamphetamine, either
|
18 | | directly or indirectly, by extraction from substances of |
19 | | natural origin,
or independently by means of chemical |
20 | | synthesis, or by a combination of
extraction and chemical |
21 | | synthesis, and includes any packaging or
repackaging of the |
22 | | substance or labeling of its container, except that
this term |
23 | | does not include:
|
24 | | (1) by an ultimate user, the preparation or compounding |
25 | | of a
controlled substance for his or her own use; or
|
26 | | (2) by a practitioner, or his or her authorized agent |
|
| | SB3109 Enrolled | - 19 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | under his or her
supervision, the preparation, |
2 | | compounding, packaging, or labeling of a
controlled |
3 | | substance:
|
4 | | (a) as an incident to his or her administering or |
5 | | dispensing of a
controlled substance in the course of |
6 | | his or her professional practice; or
|
7 | | (b) as an incident to lawful research, teaching or |
8 | | chemical
analysis and not for sale.
|
9 | | (z-1) (Blank).
|
10 | | (z-5) "Medication shopping" means the conduct prohibited |
11 | | under subsection (a) of Section 314.5 of this Act. |
12 | | (z-10) "Mid-level practitioner" means (i) a physician |
13 | | assistant who has been delegated authority to prescribe through |
14 | | a written delegation of authority by a physician licensed to |
15 | | practice medicine in all of its branches, in accordance with |
16 | | Section 7.5 of the Physician Assistant Practice Act of 1987, |
17 | | (ii) an advanced practice nurse who has been delegated |
18 | | authority to prescribe through a written delegation of |
19 | | authority by a physician licensed to practice medicine in all |
20 | | of its branches or by a podiatric physician, in accordance with |
21 | | Section 65-40 of the Nurse Practice Act, or (iii) an animal |
22 | | euthanasia agency. |
23 | | (aa) "Narcotic drug" means any of the following, whether |
24 | | produced
directly or indirectly by extraction from substances |
25 | | of vegetable origin,
or independently by means of chemical |
26 | | synthesis, or by a combination of
extraction and chemical |
|
| | SB3109 Enrolled | - 20 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | synthesis:
|
2 | | (1) opium, opiates, derivatives of opium and opiates, |
3 | | including their isomers, esters, ethers, salts, and salts |
4 | | of isomers, esters, and ethers, whenever the existence of |
5 | | such isomers, esters, ethers, and salts is possible within |
6 | | the specific chemical designation; however the term |
7 | | "narcotic drug" does not include the isoquinoline |
8 | | alkaloids of opium;
|
9 | | (2) (blank);
|
10 | | (3) opium poppy and poppy straw;
|
11 | | (4) coca leaves, except coca leaves and extracts of |
12 | | coca leaves from which substantially all of the cocaine and |
13 | | ecgonine, and their isomers, derivatives and salts, have |
14 | | been removed;
|
15 | | (5) cocaine, its salts, optical and geometric isomers, |
16 | | and salts of isomers; |
17 | | (6) ecgonine, its derivatives, their salts, isomers, |
18 | | and salts of isomers; |
19 | | (7) any compound, mixture, or preparation which |
20 | | contains any quantity of any of the substances referred to |
21 | | in subparagraphs (1) through (6). |
22 | | (bb) "Nurse" means a registered nurse licensed under the
|
23 | | Nurse Practice Act.
|
24 | | (cc) (Blank).
|
25 | | (dd) "Opiate" means any substance having an addiction |
26 | | forming or
addiction sustaining liability similar to morphine |
|
| | SB3109 Enrolled | - 21 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | or being capable of
conversion into a drug having addiction |
2 | | forming or addiction sustaining
liability.
|
3 | | (ee) "Opium poppy" means the plant of the species Papaver
|
4 | | somniferum L., except its seeds.
|
5 | | (ee-5) "Oral dosage" means a tablet, capsule, elixir, or |
6 | | solution or other liquid form of medication intended for |
7 | | administration by mouth, but the term does not include a form |
8 | | of medication intended for buccal, sublingual, or transmucosal |
9 | | administration. |
10 | | (ff) "Parole and Pardon Board" means the Parole and Pardon |
11 | | Board of
the State of Illinois or its successor agency.
|
12 | | (gg) "Person" means any individual, corporation, |
13 | | mail-order pharmacy,
government or governmental subdivision or |
14 | | agency, business trust, estate,
trust, partnership or |
15 | | association, or any other entity.
|
16 | | (hh) "Pharmacist" means any person who holds a license or |
17 | | certificate of
registration as a registered pharmacist, a local |
18 | | registered pharmacist
or a registered assistant pharmacist |
19 | | under the Pharmacy Practice Act.
|
20 | | (ii) "Pharmacy" means any store, ship or other place in |
21 | | which
pharmacy is authorized to be practiced under the Pharmacy |
22 | | Practice Act.
|
23 | | (ii-5) "Pharmacy shopping" means the conduct prohibited |
24 | | under subsection (b) of Section 314.5 of this Act. |
25 | | (ii-10) "Physician" (except when the context otherwise |
26 | | requires) means a person licensed to practice medicine in all |
|
| | SB3109 Enrolled | - 22 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | of its branches. |
2 | | (jj) "Poppy straw" means all parts, except the seeds, of |
3 | | the opium
poppy, after mowing.
|
4 | | (kk) "Practitioner" means a physician licensed to practice |
5 | | medicine in all
its branches, dentist, optometrist, podiatric |
6 | | physician,
veterinarian, scientific investigator, pharmacist, |
7 | | physician assistant,
advanced practice nurse,
licensed |
8 | | practical
nurse, registered nurse, hospital, laboratory, or |
9 | | pharmacy, or other
person licensed, registered, or otherwise |
10 | | lawfully permitted by the
United States or this State to |
11 | | distribute, dispense, conduct research
with respect to, |
12 | | administer or use in teaching or chemical analysis, a
|
13 | | controlled substance in the course of professional practice or |
14 | | research.
|
15 | | (ll) "Pre-printed prescription" means a written |
16 | | prescription upon which
the designated drug has been indicated |
17 | | prior to the time of issuance; the term does not mean a written |
18 | | prescription that is individually generated by machine or |
19 | | computer in the prescriber's office.
|
20 | | (mm) "Prescriber" means a physician licensed to practice |
21 | | medicine in all
its branches, dentist, optometrist, podiatric |
22 | | physician or
veterinarian who issues a prescription, a |
23 | | physician assistant who
issues a
prescription for a controlled |
24 | | substance
in accordance
with Section 303.05, a written |
25 | | delegation, and a written supervision agreement required under |
26 | | Section 7.5
of the
Physician Assistant Practice Act of 1987, or |
|
| | SB3109 Enrolled | - 23 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | an advanced practice
nurse with prescriptive authority |
2 | | delegated under Section 65-40 of the Nurse Practice Act and in |
3 | | accordance with Section 303.05, a written delegation,
and a |
4 | | written
collaborative agreement under Section 65-35 of the |
5 | | Nurse Practice Act.
|
6 | | (nn) "Prescription" means a written, facsimile, or oral |
7 | | order, or an electronic order that complies with applicable |
8 | | federal requirements,
of
a physician licensed to practice |
9 | | medicine in all its branches,
dentist, podiatric physician or |
10 | | veterinarian for any controlled
substance, of an optometrist |
11 | | for a Schedule II, III, IV, or V controlled substance in |
12 | | accordance with Section 15.1 of the Illinois Optometric |
13 | | Practice Act of 1987, of a physician assistant for a
controlled |
14 | | substance
in accordance with Section 303.05, a written |
15 | | delegation, and a written supervision agreement required under
|
16 | | Section 7.5 of the
Physician Assistant Practice Act of 1987, or |
17 | | of an advanced practice
nurse with prescriptive authority |
18 | | delegated under Section 65-40 of the Nurse Practice Act who |
19 | | issues a prescription for a
controlled substance in accordance
|
20 | | with
Section 303.05, a written delegation, and a written |
21 | | collaborative agreement under Section 65-35 of the Nurse |
22 | | Practice Act when required by law.
|
23 | | (nn-5) "Prescription Information Library" (PIL) means an |
24 | | electronic library that contains reported controlled substance |
25 | | data. |
26 | | (nn-10) "Prescription Monitoring Program" (PMP) means the |
|
| | SB3109 Enrolled | - 24 - | LRB098 18318 ZMM 53453 b |
|
|
1 | | entity that collects, tracks, and stores reported data on |
2 | | controlled substances and select drugs pursuant to Section 316. |
3 | | (oo) "Production" or "produce" means manufacture, |
4 | | planting,
cultivating, growing, or harvesting of a controlled |
5 | | substance other than methamphetamine.
|
6 | | (pp) "Registrant" means every person who is required to |
7 | | register
under Section 302 of this Act.
|
8 | | (qq) "Registry number" means the number assigned to each |
9 | | person
authorized to handle controlled substances under the |
10 | | laws of the United
States and of this State.
|
11 | | (qq-5) "Secretary" means, as the context requires, either |
12 | | the Secretary of the Department or the Secretary of the |
13 | | Department of Financial and Professional Regulation, and the |
14 | | Secretary's designated agents. |
15 | | (rr) "State" includes the State of Illinois and any state, |
16 | | district,
commonwealth, territory, insular possession thereof, |
17 | | and any area
subject to the legal authority of the United |
18 | | States of America.
|
19 | | (rr-5) "Stimulant" means any drug that (i) causes an |
20 | | overall excitation of central nervous system functions, (ii) |
21 | | causes impaired consciousness and awareness, and (iii) can be |
22 | | habit-forming or lead to a substance abuse problem, including |
23 | | but not limited to amphetamines and their analogs, |
24 | | methylphenidate and its analogs, cocaine, and phencyclidine |
25 | | and its analogs. |
26 | | (ss) "Ultimate user" means a person who lawfully possesses |